Hologic, Inc. (NASDAQ:HOLX) – Analysts at Leerink Swann reduced their FY2018 EPS estimates for shares of Hologic in a research report issued to clients and investors on Thursday. Leerink Swann analyst R. Newitter now forecasts that the medical equipment provider will post earnings of $2.15 per share for the year, down from their previous forecast of $2.17. Leerink Swann also issued estimates for Hologic’s FY2019 earnings at $2.38 EPS and FY2020 earnings at $2.65 EPS.

Several other equities research analysts also recently weighed in on HOLX. Royal Bank Of Canada reissued a “sector perform” rating and set a $45.00 price objective (down previously from $50.00) on shares of Hologic in a report on Wednesday, August 9th. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Barclays PLC reissued an “equal weight” rating and set a $51.00 price objective (down previously from $53.00) on shares of Hologic in a report on Wednesday, August 9th. Needham & Company LLC reissued a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. Finally, Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. Hologic has a consensus rating of “Hold” and a consensus target price of $47.77.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/13/brokers-set-expectations-for-hologic-inc-s-fy2018-earnings-holx.html.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same quarter in the prior year, the firm posted $0.51 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year.

Several large investors have recently made changes to their positions in the company. Curbstone Financial Management Corp lifted its stake in shares of Hologic by 101.2% in the 3rd quarter. Curbstone Financial Management Corp now owns 17,456 shares of the medical equipment provider’s stock valued at $640,000 after purchasing an additional 8,778 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic in the 2nd quarter valued at about $191,000. Lord Abbett & CO. LLC lifted its stake in shares of Hologic by 78.8% in the 2nd quarter. Lord Abbett & CO. LLC now owns 432,716 shares of the medical equipment provider’s stock valued at $19,637,000 after purchasing an additional 190,714 shares during the period. USA Financial Portformulas Corp acquired a new position in shares of Hologic in the 2nd quarter valued at about $2,949,000. Finally, Hall Laurie J Trustee lifted its stake in shares of Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the period. 96.38% of the stock is currently owned by institutional investors.

In other news, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total value of $276,908.24. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Insiders sold a total of 35,479 shares of company stock worth $1,388,236 over the last three months. 0.79% of the stock is owned by company insiders.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.